Lanean...
Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity
The candidate pan-Human Papillomavirus (HPV) vaccine RG1-VLP are HPV16 major capsid protein L1 virus-like-particles (VLP) comprising a type-common epitope of HPV16 minor capsid protein L2 (RG1; aa17–36). Vaccinations have previously demonstrated efficacy against genital high-risk (hr), low-risk (lr)...
Gorde:
| Argitaratua izan da: | Vaccine |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6832690/ https://ncbi.nlm.nih.gov/pubmed/31147274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2019.05.011 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|